Ticrynafen‐Associated Hepatic Injury: Analysis of 340 Cases
Hyman J. Zimmerman, James H. Lewis, Kamal G. Ishak, Willis C. Maddrey – 1 March 1984 – Ticrynafen, a uricosuric diuretic, was withdrawn from clinical use in the United States in 1980 after having been implicated as the cause of a number of instances of serious hepatic injury. In this report, we analyze 340 cases of ticrynafen‐associated hepatic disease reported to the manufacturer from the time of initial marketing until shortly after the drug had been recalled. Jaundice was recorded in 246 of 287 patients with sufficient clinical information, and 25 (10.2%) of these icteric patients died.